ASCRS 2023: Risk factors for glaucoma after infantile cataract surgery
May 7th 2023In this recent study, Bharti Nihalani-Gangwani, MD, and Deborah VanderVeen, MD, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting in San Diego.
ASCRS 2023: Negative effects of several contraceptive modalities on dry eye
May 7th 2023Lucie Moore, BSc, in a presentation at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, said the study focused on identifying factors that could put patients at a higher risk for developing dry eye disease.
ASCRS 2023: Manifestations of chronic renal insufficiency in the eye
May 6th 2023Umida F. Mavlyanova, PhD, in a presentation at the American Society for Cataract and Refractive Surgery’s annual meeting in San Diego, detailed how patients diagnosed with end-stage chronic renal failure displayed deceased blood flow in the orbital artery, the central artery of the retina and the posterior short ciliary arteries.
ASCRS 2023: Signs of progressive keratoconus in the hair and eyes
May 6th 2023Speaking at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Marcony Santhiago, MD, points out there are subtle differences in patients with keratoconus that was progressing compared with patients whose disease was stable and healthy control subjects.
ASCRS 2023: Using IOL to alter choroidal thickness after cataract surgery
May 6th 2023In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Erisa Yotsukura, MD, PhD, offered details of a study examining an IOL that transmits violet light and a second option that does not, and they believe this can affect differences in the choroidal thickness after cataract surgery.
ASCRS 2023: Clinical trials find CSF-1 provides visual improvement in mild to moderate presbyopia
May 6th 2023Preeya Gupta, MD, reported results of the trials at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, showed that CSF-1, a low dose pilocarpine with an optimized formulation, demonstrated significant 2-line improvement from baseline.
ASCRS 2023: Cenegermin 0.002%: Effective for corneal nerve regeneration in neurotrophic keratitis
May 5th 2023In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.
Eye rubbing plays role in keratoconus and ocular surface disease progression
April 12th 2023The authors conducted a prospective non-interventional study in which a self-questionnaire was used to evaluate the ocular symptoms and medical background of patients with KC and OSD who engage in chronic eye rubbing.
3-week therapeutics for MGD equivalent to 6-week treatment in efficacy and adverse events
March 27th 2023Investigators reported that moderate to severe Meibomian gland dysfunction (MGD) was treated successfully with a 3-week course of weekly oral azithromycin that was equivalent to a 6-week course of oral doxycyclin.